Why is H Lundbeck stock falling today?

H. Lundbeck B shares fell 5.3% to DKK 42.28 after Deutsche Bank downgraded the stock to Sell from Hold and cut its target price to DKK 36, implying about 18% additional downside. The downgrade cites risks to Rexulti, which represents roughly 25% of revenue, from Auvelity competition and an IRA-related price cut scheduled for 2028. An ongoing 1:1 A-to-B share exchange offer through September 16, 2026 is adding near-term B-share dilution pressure, while broader risk-off equity markets provide little support.

Analysis

The key near-term mechanism is technical rather than fundamental: the A-to-B conversion increases tradable B-share supply but does not dilute Lundbeck’s underlying economics. With the exchange window ending imminently, forced or arbitrage-related selling should largely clear thereafter; a continued B-share decline after settlement would be a more credible signal that investors are repricing the earnings base rather than simply absorbing incremental float. This makes chasing the current selloff unattractive without evidence that B-share volume remains elevated beyond the settlement period.

The more durable risk is that Rexulti’s contribution has unusually high operating leverage: lost U.S. share or net-price erosion would likely flow disproportionately to EBIT because commercial infrastructure is already in place. Axsome Therapeutics (AXSM) is the cleaner competitive read-through, but its upside depends on Auvelity uptake translating into substitution rather than category expansion; prescription-share data and Lundbeck’s next U.S. guidance are the relevant 1-3 month catalysts. The 2028 pricing reset is a 6-18 month valuation overhang, yet the market may be pulling forward a risk whose actual impact depends on negotiated net pricing and lifecycle-management actions.

Contrarianly, the analyst’s low-multiple framework may be directionally correct but not independently establishes a downside catalyst from current levels. A post-exchange B-share rebound is plausible if the incremental supply was the marginal seller and management maintains 2026-27 EBIT guidance; conversely, a guidance cut, Rexulti prescription deceleration, or accelerated Auvelity share gains would validate a structural de-rating toward the mid-DKK 30s. DB is not a useful sector short proxy here; its rating action has limited direct earnings relevance for the bank.

Key Decisions for Investors

• Do not initiate an outright HLUN.B short before the exchange-offer settlement clears. Reassess 5-10 trading days after September 16: short only if B-share volume remains above normal and the stock fails to reclaim DKK 42; target DKK 36-37 over 1-3 months, with a stop above DKK 44.50.
• Set an A-share/B-share spread monitor immediately. If the A share trades at a material discount to HLUN.B after accounting for conversion mechanics and settlement timing, buy A versus short B as a market-neutral convergence trade; require live prices, borrow availability, and settlement terms before execution.
• Use AXSM as a watch-list long rather than a direct recommendation: initiate only on independently verified Auvelity prescription-share acceleration and reiterated 2026 guidance. The thesis is falsified if category growth, rather than Rexulti substitution, drives prescriptions or if AXSM commercial spending absorbs incremental gross profit.
• For existing HLUN.B longs, reduce exposure into the next earnings update unless management explicitly quantifies Rexulti volume, net-price, and 2027 EBIT sensitivity. Retain only if guidance is maintained and post-conversion selling exhausts; a break below DKK 35 would indicate the technical-support thesis has failed.